Since their discovery in the late 1970s, protein kinase C (PKC) isozymes represent one of the most extensively studied signaling kinases. PKCs signal through multiple pathways and control the expression of genes relevant for cell cycle progression, tumorigenesis and metastatic dissemination. Despite the vast amount of information concerning the mechanisms that control PKC activation and function in cellular models, the relevance of individual PKC isozymes in the progression of human cancer is still a matter of controversy. Although the expression of PKC isozymes is altered in multiple cancer types, the causal relationship between such changes and the initiation and progression of the disease remains poorly defined. Animal models developed in the last years helped to better understand the involvement of individual PKCs in various cancer types and in the context of specific oncogenic alterations. Unraveling the enormous complexity in the mechanisms by which PKC isozymes have an impact on tumorigenesis and metastasis is key for reassessing their potential as pharmacological targets for cancer treatment.
INTRODUCTION
Protein kinase C (PKC), a prototypical class of serine/threonine kinases, exemplifies specific signaling molecules that link multiple cellular processes to cancer. Originally identified as a cellular receptor for the phorbol ester tumor promoters more than 30 years ago, 1-2 PKC became the subject of intense studies by academic laboratories and pharmaceutical companies (450 000 citations in PubMed, which is even more than other ABC kinases such as PKA or PKB/Akt). Extensive work established these kinases as pleiotropic regulators of cell function, including proliferation, differentiation, survival and motility. 3 To date, it is clear that PKCs are associated with a number of diseases, including cancer, cardiovascular dysfunctions and metabolic disorders. The complexity in PKC signaling arises from the fact that PKC is a multifamily of structurally related kinases with diverse biological functions. Indeed, mammalian PKCs encompass 10 members that represent the products of nine different genes located in different chromosomes. PKC isozymes have been classified into three groups: 'conventional' or 'classical' PKCs (cPKCs) that are composed of PKCa, two splice variants of PKCb (PKCbI and PKCbII) and PKCg; 'novel' PKCs (nPKCs), a group that includes PKCd, PKCe, PKCZ and PKCy; and 'atypical' PKCs (aPKCs) z and i (l). cPKCs and nPKCs are activated by diacylglycerol (DAG), a lipid second messenger transiently generated upon stimulation of membrane receptors such as tyrosine-kinase and G-proteincoupled receptors. DAG mimics the action of phorbol esters, as they bind to the C1 domains in the regulatory region. Only the cPKCs are calcium-sensitive, as they have a calcium-binding C2 domain (the C2 domain in nPKCs is calcium-insensitive). aPKCs display unique regulatory properties: they are unable to bind DAG or calcium and rather depend on protein-protein interactions and phosphorylation for their activation 3 ( Figure 1 ). In the last years we have witnessed major advances in our understanding of the roles of PKCs in tumor development and progression, including in late stages of the disease and metastasis. This review summarizes the knowledge on PKC isozymes in cancer progression and highlights the most recent advances in the field, particularly using genetically modified mouse models in the context of specific oncogenic alterations.
PKC ISOZYME EXPRESSION IN CANCER: CHANCE OR CAUSALITY?
Expression levels of PKC isozymes change in neoplastic diseases. The overall picture is, however, confusing, partly due to potential issues of antibody specificity in immunohistochemical studies and lack of appropriate validation controls in many reports. The standing question is whether those changes in expression have any causal relationship with disease progression. An additional complication is that, in an era when microarray mRNA databases are routinely used, there are significant discrepancies between the available information on PKC expression at the mRNA and protein levels. This can be epitomized for PKCe, an isozyme that is markedly upregulated in most epithelial cancers at the protein level, [4] [5] [6] [7] but shows only marginal or no changes in mRNA databases ( Figure 2 ). Whereas high expression of PKCe in tumors may involve changes at a transcriptional level, expression underestimation by databases may relate to post-translational events that ultimately modify protein stability. Modeling expression patterns from mRNA expression databases, which in most cases have not been generated from microdissected tissues, can distort the actual profile of PKC protein expression in tumors and ultimately mislead our efforts to correlate those changes with clinicopathological outcomes.
Another important issue that received little attention is the activation status of PKC isozymes in cancer. There is little experimental evidence supporting either hyperactivation or hypoactivation of PKCs in human tumors. Unlike other important kinases implicated in cancer progression, such as Erk, JNK or Akt, phosphorylation of PKCs does not necessarily correlate with activation status. One impediment to address this important matter is the lack of reliable readouts associated with the activated status of individual PKCs, in particular PKC isozymespecific substrates that could be detected in human tumors. Genetically encoded reporters for PKC isozymes reliably detect enzyme activation and substrate phosphorylation in cellular models in culture; [8] [9] [10] [11] [12] however, we still lack tools to detect activated PKCs or their specific substrates in tumors by immunohistochemistry. The association of PKCs to membranes is a requisite for the activation of DAG/phorbol ester-regulated PKCs. 3 Whereas some exceptions have been reported, such as the activation by proteolytic cleavage, 13 cPKCs and nPKCs translocate to the plasma membrane in response to stimuli such as growth factor receptor activation. Although less understood at a mechanistic level, cPKCs and nPKCs can also redistribute to a number of intracellular compartments, including the translocation to the mitochondria, Golgi, endoplasmic reticulum and nuclear membrane. Constitutive association of PKCs to internal membranes has also been reported. [14] [15] [16] [17] At present, we do not understand well the significance of such compartmentalization and whether PKCs are fully activated in discrete intracellular locations due to differential membrane compositions, DAG availability, and/or the presence of isozyme-specific protein partners that cooperate for the transition to an activated status. All these factors conspire against a full appreciation on how PKC activation contributes to disease progression.
PKCa: TUMOR PROMOTER OR TUMOR SUPPRESSOR?
PKCa has been long recognized as a regulator of multiple aspects of tumor growth, including proliferation, survival, differentiation and motility. As several studies linked PKCa to enhanced proliferation and anti-apoptotic signals, [18] [19] [20] [21] [22] there has been significant interest in this kinase as a potential target for cancer therapy. However, PKCa had limited success as a drug target for cancer. Indeed, due to its very complex and highly tissue-specific functions, PKCa acts as a tumor promoter or a tumor suppressor depending on the context. To add another level of complexity, PKCa is upregulated in some Figure 1 . Structure of PKC isozymes. PKCs are multidomain proteins that are regulated by lipids and protein-protein interactions. DAG generated upon activation of receptors causes the activation of cPKCs and nPKCs, and its actions are mimicked by phorbol esters. aPKCs do not respond to DAG or phorbol esters. PKCs activate a number of signal transduction pathways that regulate tumorigenesis and metastasis. This meta-analysis shows non-statistically significant differences in PRKCE mRNA expression (combined P-value ¼ 0.41) between normal and prostate cancer groups. Red intensity is a representative of the statistical significance in mean difference between normal and prostate cancer for each study. (c) Expression of PKCe in 'normal' immortalized prostate epithelial RWPE-1 cells versus prostate cancer cells. This figure was originally published by Garg et al., 176 The American Society for Biochemistry and Molecular Biology.
cancers (such as bladder, endometrial and breast cancer) and downregulated in others (such as colorectal tumors and malignant renal cell carcinomas 23, 24 ). There is little information on substrates specifically phosphorylated by PKCa or genetic programs controlled by PKCa, thus rendering our comprehension of the molecular basis of this functional diversity incomplete.
Early studies in glioma cellular models established that PKCa is upregulated relative to astrocytes. Antisense oligonucleotides against PKCa inhibit the proliferation of glioma cells. 25 Consistent with these results, overexpression of PKCa in U87 glioblastoma cells enhances proliferation. Although overexpression of PKCa did not protect U87 cells from apoptosis by etoposide, other studies documented that PKCa renders enhanced resistance to apoptosis in response to radiation and chemotherapy. 18, 26, 27 In U1242 glioblastoma cells, PKCa regulates the activation of nuclear factor kappa B (NF-kB), which results in a pro-survival phenotype. 28 Aprinocarsen (Ly900003, ISIS 3521), an antisense oligonucleotide directed against the 3 0 -untranslated region of PKCa, arrests A172 glioma cells and induces p53. Aprinocarsen also impairs tumor growth in xenograft models. In combination with other chemotherapeutic agents, aprinocarsen was shown to have additive or super-additive antitumor effects. [29] [30] [31] Despite encouraging responses in early clinical trials, this anti-PKCa agent failed to make it into phase III clinical trials either alone or in combination with other agents. 29 Another PKCa inhibitor, the staurosporine analogue UCN-01 32 proved to be a potent antitumor agent in preclinical models, but its effect cannot be explained simply by PKCa inhibition. 33 It is also intriguing that PKCa RNA interference depletion but not PKCa inhibition impairs the growth of glioma cell lines, suggesting that the effect is independent of the catalytic phosphotransferase activity of the enzyme. 18 Another interesting link between PKCa and cancer progression has been established in breast. Ways et al. 34 showed that ectopic overexpression of PKCa in MCF-7 breast cancer cells (which express low levels of PKCa) enhances proliferative rate, confers anchorage-independent growth and tumorigenic potential in nude mice, and drastically alters cell shape by inducing loss of an epithelioid morphology. PKCa overexpressing MCF-7 cells have reduced estrogen receptor (ER) levels, suggesting that PKCa contributes to the switch from ER-positive to ER-negative status. Likewise, Tonetti et al. 35 found that stable overexpression of PKCa in T47-D breast cancer cells is accompanied by downregulation of ER function and confers hormone-independent tumor growth that cannot be inhibited by tamoxifen. 36 A recent study suggests that this effect may be mediated by Notch-4. 37 Elevated PKCa expression was suggested to be a predictor of tamoxifen treatment failure, which fits with the observation that patient tumor samples with elevated PKCa levels are generally negative for ER expression, and these patients respond less to endocrine therapy. 38 Go6976, a pharmacological inhibitor of cPKCs, 42 abrogates ErbB2-mediated upregulation of urokinase-type plasminogen activator and cell invasion. 43 Whereas PKCa expression is higher in triplenegative breast cancers than in other subtypes, 44 we still need to underscore meaningful associations of this PKC with genetic alterations specific for each breast cancer subtype.
In a very recent study by the Weinberg laboratory, PKCa was found to be enriched in epithelial-to-mesenchymal-induced mammary cells. 45 Interestingly, inhibitors targeting PKCa preferentially kill mesenchymal cells relative to epithelial cell lines, and likewise, depletion of PKCa using small hairpin RNA results in a substantial loss of mesenchymal cells. A PKCa signaling network is activated preferentially in cancer stem cells by plateletderived growth factor and involves the transcription factor FRA1 (Fos-related antigen 1). The activation of the PDGFR-PKCa-FRA1 pathway in breast cancer stem cells makes them particularly susceptible to pharmacological inhibition of PKCa. Whereas the relevance of this pathway has to be established in other cancer types, this study certainly shed light into the potential therapeutic value of targeting PKCa in epithelial cancers.
Despite the reported pro-tumorigenic effects of PKCa, it has been also described as a growth inhibitory kinase in several cell types. For example, activation of PKCa in non-small cell lung cancer (NSCLC) cells leads to p21
Cip1 upregulation, inhibition of cell growth and senescence. 46 Not surprisingly, aprinocarsen showed no significant benefit for NSCLC patients, either alone or in combination with other chemotherapeutic agents. 29 Years ago, Black and coworkers 47, 48 reported that PKCa activation triggers a program of cell cycle exit-specific events in intestinal crypts through the repression of cyclin D1 translation. This effect implicates the activation of the translational repressor 4E-BP1 through a phosphatase 2A-dependent mechanism and in a PI3K/Akt-independent manner. 49 PKCa also inhibits the Wnt/bcatenin pathway in colon cancer cells and represses the expression of b-catenin target genes such as c-Myc, 50 a mechanism that may involve receptor-related orphan receptor alpha RORa. 51 Interestingly, a small-molecule screening identified a compound (CGK062) that promotes PKCa-mediated phosphorylation of bcatenin, leading to its proteasomal degradation. This compound has antitumor effects in nude mice. 52 The expression of PKCa in proliferating intestinal epithelial cells is repressed both in vitro and in vivo by the SOX9 transcription factor. 53 All neoplasm arising in APC À / þ mice, which develop multiple intestinal neoplasia, express low levels of PKCa. Remarkably, loss of PKCa directly correlates with aggressiveness of intestinal tumors. Furthermore, tumor formation and aggressiveness are enhanced in double transgenic APC Min/ þ ; PKCa À / À mice ( Figure 3a) . Interestingly, spontaneous intestinal tumors develop in PKCa À / À mice. 54, 55 PKCa also suppresses skin tumor formation induced by DMBA (7,12-dimethylbenz[a]anthracene). However, PKCa deficiency does not alter the size or malignancy of skin tumors. 56 PKCa activation by phorbol esters contributes to cell death in androgen-dependent prostate cancer cells. Activation of PKCa in LNCaP cells leads to a rapid and reversible dephosphorylation of Akt possibly via activation of a protein phosphatase 2A phosphatase. 57 Stable DAG analogues with preferred selectivity for PKCa also induce apoptosis in LNCaP cells. 58 A kinase-dead PKCa mutant blocks the apoptotic response elicited by a combination of phorbol 12-myristate 13-acetate (PMA) treatment and radiation, and a constitutively active PKCa mutant sensitizes cells to radiation treatment. Although radiation alone reduces initial LNCaP tumor growth and serum prostate-specific antigen levels in mice, combinatorial treatment with PMA or a specific PKCa DAG activator eliminates tumor growth and drastically reduces prostate-specific antigen levels. 59 A very interesting recent study by the group of Alan Fields reported that PKCa has a key role in K-Ras-mediated lung tumorigenesis. 60 There is an evident loss of expression of PKCa in primary human NSCLC tumors. Remarkably, PKCa-knockout mice display enhanced K-Ras lung tumorigenesis (Figure 3b ) and bypass oncogene-induced senescence. The tumor promoting effect caused by loss of PKCa may involve the expansion of bronchoalveolar stem cells. Mechanistic analysis determined that loss of PKCa reduces the activation of p38 mitogen-activated protein kinase in bronchoalveolar stem cells from K-Ras tumors and augments transforming growth factor b1 (TGFb1) mRNA levels. Moreover, a TGFb receptor inhibitor reversed the effect of PKCa loss in K-Ras/PKCa-depleted tumors. This study reported the inhibitors of DNA binding (Id) Id1-3 as potential downstream targets of PKCa-dependent tumor suppressor activity, as also observed in other intestinal cells and fibroblasts. 61, 62 Therefore, PKCa suppresses tumor initiation and progression in the K-Ras lung cancer mouse model through a p38 mitogen-activated protein kinase/TGFb signaling axis.
PKCa has been implicated in invasion and metastasis, mostly as a positive regulator. [63] [64] [65] [66] [67] [68] In breast cancer cells, ErbB2-dependent activation of PKCa promotes cell invasion. 41 PKCa overexpressing MCF-7 breast cancer cells display enhanced motility, which was attributed to decreased expression of E-cadherin and b-catenin and high expression of matrix metalloprotease (MMP)-2/MMP-9. 69, 70 A specific PKCa peptide inhibitor significantly reduced metastasis of mouse mammary cancer cells to the lungs. Analysis of highly metastatic (4T1) and nonmetastatic (JC) mouse mammary cells indicates that the basal activation of PKCa is higher in the former. Treatment with this PKCa antagonistic peptide did not affect tumor growth but blocked metastasis of 4T1 cells to the lungs. PKCa inhibition blocks metastasis by inhibiting the activation of MMPs in combination with decreased NF-kB activity and CXCL12 receptor levels. 71 PKCb ISOZYMES: SPLICED VARIANTS WITH DISTINCT INVOLVEMENT IN CANCER PKCbI and PKCbII, spliced variants encoded by the PRKCB gene have differential tissue expression and a distinct involvement in cancer. PKCb isoforms have been implicated in the progression of many cancer types, including lymphoma, glioblastoma, breast, prostate and colorectal cancers. [72] [73] [74] [75] [76] It is not fully understood why PKCb isoforms have in some cases different functions. This may relate to unique lipid-and protein interactions via their different C-terminal domains that confer distinctive localization properties. [77] [78] [79] However, many studies using pharmacological agents do not distinguish between PKCb subtypes.
Early studies reported elevated PKCbII levels both during the initial stages of tumorigenesis and in colonic carcinomas relative to normal colonic tissue. [80] [81] [82] Spindler et al. 83 reported that 18% of primary adenocarcinomas exhibit very high levels of PKCbII, which correlates with poor survival rates. PKCbII has been implicated in colon cancer cell proliferation in vitro.
84, 85 Murray et al. 86 generated a transgenic mouse model overexpressing PKCbII in the intestinal epithelium. In addition to epithelial hyperproliferation, these mice display increased susceptibility to carcinogen-induced preneoplastic lesions in the colon. The phenotype has been linked to repression of TGFb signaling and elevated COX-2 expression. 72 In the proximal colon, activated K-Ras induces the expression of PKCbII, activation of the Mek/Erk signaling axis and increased epithelial cell proliferation. 87 In a cellular model of intestinal cells, stable overexpression of PKCbII confers an invasive phenotype mediated by a Ras/Mek/PKCi/Rac1-dependent pathway. 88 The role of PKCbI in the colon is less clear. Overexpression of PKCbI suppresses the growth of HT29 and SW480 colon cancer cell xenograft. 89 However, other report shows that expression of PKCbI confers resistance to apoptosis by tumor necrosis factor a (TNFa) and paclitaxel. 90 PKCbI expression positively correlates with high Gleason scores in prostate carcinomas, and inhibition of this kinase blocks androgen receptor-induced tumor cell proliferation in vitro and xenograft growth in vivo. Notably, PKCbI phosphorylates histone H3 and inhibits androgen-dependent transcription. 91 A study using a specific PKCbII peptide inhibitor showed that this isoform is involved in prostate cancer cell proliferation. PKCbII also has an important role in endothelial cell proliferation, and inhibition of PKCbII reduces angiogenesis. These effects were linked to dysregulation of cytokinesis and microtubule organization. 73 Enzastaurin, an inhibitor with some degree of specificity toward PKCb, displays antiproliferative effects in PC-3 cells. 92 Overexpression of either PKCbI or PKCbII in MCF-7 breast cancer cells promotes cell growth and enhances cyclin D1 levels, whereas dominant-negative PKCb mutants inhibit growth. 93 On the other hand, another report showed that PKCbI overexpression induces a less aggressive biological behavior in MCF-7 cells characterized by reduced tumor formation. 94 In a murine mammary model, PKCbI inhibits tumorigenesis despite having a positive effect on growth in culture. Moreover, tumor cells that overexpress PKCbI have attenuated metastatic capacity to the lungs. 95 Enzastaurin has significant effects on the growth of breast cancer cells in vitro and in vivo. 96, 97 High levels of PKCbII have been reported in several breast cancer cell lines and patient samples. The levels of cytoplasmic PKCbII expression positively correlate with ErbB2/Her2 levels, whereas nuclear PKCbII positively correlates with ER levels. 98 PKCbII is expressed in human NSCLC specimens with significant variability, both in tumor cells and the stroma. 99 Enzastaurin in combination with the antifolate pemetrexed causes G2/M checkpoint abrogation and apoptosis in lung cancer cells. 100 In cell culture, enzastaurin is a potent inhibitor of vascular endothelial growth factor-stimulated proliferation of endothelial cells, and in vivo this inhibitor causes a significant reduction in intratumoral vessels that parallels a delay in lung cancer tumor growth. 99 Enzastaurin also enhances the anti-angiogenic effects of radiation in NSCLC models. 101 The PKCb inhibitor, Enzastaurin, regulates proliferation of glioblastoma cells by supporting the activity of GSK3, S6 kinase and Akt. 102 The effect of the PKCb inhibitor was also shown in U87MG human glioblastoma cells inoculated into nude mice. Enzastaurin proved to be efficient as an antiangiogenic compound in models of glioblastoma, 76 however clinical trials in patients with recurrent high-grade glioma show limited success when this inhibitor was used as a monotherapy. 103 Patients with diffuse large B-cell lymphoma that express PKCb have reduced overall survival compared with those that are negative for this kinase. 104, 105 Enzastaurin displays pro-apoptotic properties in T-cell and B-cell lymphoma cell lines. 106, 107 There is significant interest in using this PKCb inhibitor for the treatment of various types of lymphomas, both as a single agent and in combination therapies. 108, 109 Taking advantage of a PKCbknockout mouse model, it has been recently demonstrated that stromal PKCbII is indispensable for the survival of chronic lymphocytic leukemia B cells. The fact that stromal PKCbII is upregulated in biopsies from patients with chronic lymphocytic leukemia , and that chronic lymphocytic leukemia cells induce the expression of stromal PKCb, 110 highlights the need to better understand how this PKC contributes to cancer development in the context of the different tumor microenvironments.
PKCd: COMPLEX ROLES IN APOPTOSIS, TUMOR GROWTH AND METASTASIS
PKCd has been widely characterized as a pro-apoptotic and antiproliferative kinase. In addition, PKCd has been broadly implicated as a death mediator of chemotherapeutic agents and radiotherapy. [111] [112] [113] [114] PKCd is involved both in DNA damage and receptor-mediated cell death. 3, 114, 115 Initial work from the Reyland lab showed that PKCd is cleaved by caspase-3 and mobilizes from the cytoplasm to the nucleus after treatment with genotoxic agents. 13 Other studies showed that PKCd-mediated apoptosis involves the allosteric activation of the enzyme rather than proteolytic cleavage. For example, in androgen-dependent prostate cancer cells, PKCd activation triggers an apoptotic response without the generation of a constitutively active catalytic fragment. 116 This effect involves the activation of the p38 mitogen-activated protein kinase cascade 57 and is mediated by a RhoA/ROCK/p21 Cip1 -dependent pathway. 117 PKCd-mediated apoptosis in androgen-dependent prostate cancer cells occurs through the autocrine secretion of TNFa and TNF-related apoptosis-inducing ligand, which induce caspase-8 cleavage through the JNK and p38 mitogen-activated protein kinase cascades. [118] [119] [120] The discrepancies in the mechanisms of PKCd activation among the various studies may be explained by cell type differences and nature of the stimulus.
An inhibitory role for PKCd in proliferation has been reported in a number of cellular models. The initial observations by Mischak et al. 121 that ectopic overexpression of PKCd confers growth inhibitory properties to NIH 3T3 cells, were later recapitulated in many other cell lines. Depending on the cell type, activation of PKCd can induce cell cycle arrest either in G1 or G2. 48, 122 Our laboratory showed that treatment of lung cancer cells with phorbol esters induces cell cycle arrest in G1 through the induction of p21 cip1 and Rb dephosphorylation. 123 However, it has been also noted that ectopic expression of PKCd stimulates quiescent cells to initiate the G1 phase cell cycle progression. Notably, PKCd-overexpressing cells arrest in S-phase rather than completing the cell cycle. 124 It is important to mention that studies ascribed pro-survival properties to PKCd in a number of tumor models, including breast, lung, pancreatic and liver cancer. 115 Moreover, ectopic expression of PKCd in mammary cells confers anchorage-independent growth properties and enhances the resistance to apoptotic stimuli. 125 The scenario that PKCd could be a tumor promoting kinase rather than a tumor suppressor began to shape new paradigms in PKC isozyme function, and clearly points to an exquisite cell type selectivity.
Data from patients cannot point to a clear link between PKCd expression levels and clinical outcome. Loss of PKCd expression has been reported in a few cancer types, [126] [127] [128] but this downregulation could not be unambiguously linked to tumorigenesis. PKCd is upregulated in some cancer types. 129, 130 PKCd is barely detected in normal prostate epithelial cells; however, high PKCd expression could be observed in prostate preneoplastic lesions and carcinomas. 131, 132 In breast cancer specimens, PKCd mRNA levels are significantly higher in ERpositive tumors and a positive correlation between high PKCd mRNA levels and reduced overall survival has been reported. 133 Interestingly, the expression of PKCy, an isozyme related to PKCd, is dysregulated in some cancers. 130, [134] [135] [136] Emerging studies using genetically engineered mice began to shed light into the involvement of PKCd in tumorigenesis. PKCd skin transgenic mice are resistant to tumor promotion by DMBA/ PMA. 137 Studies using PKCd-knockout mice revealed contrasting effects particularly in the context of specific genetic alterations. Reyland and coworkers 138 investigated the involvement of PKCd in K-Ras-dependent tumorigenesis and found that the incidence of urethane-induced lung tumors (which display activating mutations in K-Ras) is reduced in a PKCd-null background. Moreover, PKCd RNA interference depletion inhibits anchorageindependent growth, invasion, migration and tumorigenesis in K-Ras-dependent NSCLC cells. The Reyland lab also described a positive role for PKCd in mammary tumorigenesis in the context of ErbB2 overexpression. A meta-analysis of ErbB2-positive breast cancers shows increased PKCd expression and a negative correlation between PKCd expression and prognosis. Most remarkably, there is a significant delay in tumor onset in MMTVErbB2(Neu) in a PKCd-null background. 139 A tumorigenic role for PKCd has been also reported in a model of pancreatic cancer. Indeed, overexpression of PKCd (as observed in human ductal carcinomas) leads to increased anchorage-independent growth and tumorigenesis in vivo. 140 In addition, in a PC-3 xenograft model, PKCd activation promotes tumor growth and increases angiogenesis through a mechanism that involves reactive oxygen species, nicotinamide adenine dinucleotide phosphate and hypoxia-inducible factor 1a. 141 PKCd generally has a positive role in migration and invasiveness. [142] [143] [144] [145] In prostate cancer cellular models, PKCd has been implicated in invasiveness and the control of collagen secretion induced by overexpression of the oncoprotein PCPH. 132 Breast cancer models provided controversial evidence for the involvement of PKCd in invasion. Whereas a study showed that PKCd overexpression in highly motile BT-549 breast cancer cells reduces migration and PKCd downregulation enhances motility and MMP-9 secretion in MCF-7 cells 146 other study reported that enhanced migration induced by forced epidermal growth factor receptor overexpression in MCF-7 cells requires PKCd. 147 PKCd was found to inhibit the production of proteolytic enzymes in murine mammary cells, possibly limiting metastatic dissemination. 125 Downregulation of PKCd suppresses lung colonization in the murine mammary breast cancer model MTLn3 without affecting the growth of primary tumor. 148 Studies performed in BL6 murine melanoma cells showed that PKCd overexpression increases their metastatic capacity in vivo, possibly due to an increase in the plasma levels of TGF-b1. 149, 150 A similar pro-metastatic effect of PKCd has been shown in the human pancreatic cell line PANC1. 140 The multiplicity of effects regulated by PKCd and the complexity of the effects in cell cycle regulation, cell motility, tumorigenicity and metastasis, both in positive and negative manners (Figure 4) , would argue that this kinase is not a likely candidate for the therapy of cancer.
PKCe: AN ONCOGENIC AND METASTATIC KINASE PKCe has been originally described as an oncogenic kinase 121, 151, 152 and is known to signal via the Ras-Raf-1 signaling pathway [153] [154] [155] [156] as well as other pathways. PKCetransformed fibroblasts secrete increased amounts of TGF-b and possibly other mitogens, an indication that growth autocrine loops may account for its oncogenic activity 157, 158 PKCe is overexpressed in a large number of cancers. For example, PKCe is overexpressed in B75% of primary tumors from invasive ductal breast cancer patients. Increased PKCe staining correlates with high histological grade, positive ErbB2/Her2 status and negative estrogen and progesterone receptor status. 7 Overexpression of PKCe has been reported in the majority (490%) of primary NSCLC cancers relative to normal lung epithelium. 5 PKCe levels are elevated in prostate cancer relative to benign prostatic epithelia, 159 and a correlation with aggressiveness of human prostate cancer has been found. 4 PKCZ, an isoform related to PKCe, has also been shown to be upregulated in some cancers, 160, 161 but downregulated in others. 162 
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Not surprisingly, studies from several laboratories highlight a role for PKCe in cell cycle control, specifically in G1 to S progression. [163] [164] [165] In addition, PKCe promotes survival in many cell types. 6, [166] [167] [168] The survival activity of PKCe involves the modulation of caspases and Bcl-2 family members. 166, [169] [170] [171] Forced expression of PKCe in LNCaP prostate cancer cells confers resistance to PMA-induce apoptosis by preventing Bax oligomerization; moreover, it leads to accelerated proliferation of LNCaP cells due to constitutive activation of the Erk cascade. 167 Our laboratory recently demonstrated that PKCe modulates Bad phosphorylation at Ser112 to protect LNCaP prostate cancer cells against apoptosis induced by PMA or TNFa. 170 PKCe protects glioma and lung cancer cells from TNF-related apoptosis-inducing ligand-induced apoptosis. 168, 172, 173 Subsequent studies by Basu and coworkers 174 revealed that PKCe inhibits cell death in breast cancer cells, partly by preventing the activation and translocation of Bax to the mitochondria. PKCe inhibition/depletion impairs proliferation and anchorage-independent growth of human NSCLC cells. 5, 175 Many pro-apoptotic genes upregulated upon PKCe RNA interference depletion in lung cancer cells are also downregulated in human lung adenocarcinomas. 175 RWPE-1 cells, a model of normal immortalized prostate epithelial cells, express very low levels of PKCe as compared with different human prostate cancer lines, and ectopic expression of PKCe in RWPE-1 cells confers growth advantage and leads to Erk and Akt activation. 6 Recently, our laboratory identified a key role for PKCe as a mediator of NF-kB signaling in prostate cancer. 176 PKCe inhibition/depletion impairs constitutive and TNFa-dependent activation of NF-kB as well as the induction of NF-kB responsive genes pertaining to cell survival, proliferation, metastasis and invasion, such as COX-2, MMP-9, vascular endothelial growth factor and interleukin-6. 176 Overexpression of PKCe in androgen-dependent LNCaP cells initiates tumor growth in vivo both in intact and castrated athymic nude mice, 177 thereby indicating that PKCe has the potential to advance the progression of prostate cancer and initiate recurrent tumor growth in the absence of androgens. In concordance, another study found that PKCe overexpression in breast cancer cells causes tumor growth in BALB/c mice with significant increase in the incidence and number of spontaneous experimental lung metastases. 95 In line with these results, depletion of PKCe from lung cancer cells using small hairpin RNA markedly inhibited xenograft growth in nude mice. Furthermore, the PKCe translocation inhibitor peptide eV1-2 blocks NSCLC tumor growth in nude mice. Moreover, both small hairpin RNA depletion and pharmacological inhibition of PKCe causes a strong induction of cell death in xenograft tumors. 175 Unfortunately, there has been little work intending to recapitulate PKCe overexpression as observed in human cancer. Our laboratory developed prostate-specific transgenic mice that overexpress PKCe in the normal prostate in vivo under the control of the androgen-responsive probasin (PB) promoter, which leads to the formation of preneoplastic lesions ( Figure 5 ). Conversely, similar mouse models for other PKCs (PB-PKCa and PB-PKCd mice) do not display any noticeable phenotypic changes in the prostate. Furthermore, elevated phospho-Akt as well as hyperactivation of Akt effectors S6 and mTOR could be detected in hyperplasia and prostatic intraepithelial neoplastic (PIN) lesions from PB-PKCe transgenic mice. Besides, PKCe overexpression confers resistance to apoptosis induced by androgen ablation, highlighting a prosurvival role of PKCe in the mouse prostate. 6 Hyperactivation of NF-kB and Stat3 were evident in the PIN lesions of PB-PKCe transgenic mice relative to the normal areas or regions with mild hyperplasia. 6, 176 Prostates of TRAMP mice (a model that spontaneously develops progressive invasive prostate cancer) have very high PKCe protein levels compared with prostates of control mice. 4 A recent study demonstrated that genetic ablation of PKCe in TRAMP mice inhibits prostate cancer development and metastasis. 178 Deletion of PKCe in TRAMP mice decreases the phosphorylation/activation of Stat3 as well as its nuclear translocation and DNA-binding activity. It has been proposed that loss of PKCe in TRAMP transgenic mice reduces the expression of proliferation, survival and metastasis markers, including COX-2, Bcl-xL, cyclin D1 and vascular endothelial growth factor as well as it decreases serum interleukin-6 levels.
A growing body of evidence indicates that PKCe is implicated in tumor cell invasion and metastasis. Enhanced PKCe levels are associated with invasion and/or metastasis of human breast, glioma and renal cell carcinoma. 7, 164, 179 PKCe contains an actinbinding motif that positions this kinase within a cytoskeletal matrix where many PKC substrates are localized. [180] [181] [182] [183] Deletion of this motif abrogates invasion and metastatic spread of tumors driven by PKCe overexpression. 184 In human glioma cells, the PKCinteracting protein RACK1 appears to link activated PKCe to the integrin b chain at focal adhesions, and PKCe mediates the adhesion and motility of cells via Erk phosphorylation. 185 PKCe also promotes the assembly of matrix adhesions containing actin filaments and b1-integrins, and integrin signaling links PKCe to the Akt survival pathway in recurrent prostate cancer cells. 186 In models of breast and head and neck cancer, PKCe regulates motility and invasion, at least in part due to the activation of small Rho GTPases, specifically RhoA and/or RhoC. 7, 187 Very recent work from our laboratory showed that targeted disruption of PKCe in lung cancer cells reduces motility through Rac1 inactivation. Several extracellular matrix proteases are downregulated in PKCedepleted lung cancer cells. 188 Consistent with a role for PKCe in metastatic dissemination, PKCe-depleted NSCLC cells fail to colonize lungs after tail vein injection in mice. 188 Likewise, a study from the Urtreger's laboratory showed that inoculation of Figure 4 . Multiple biological functions regulated by PKCd. Studies in cellular models established important roles for PKCd in apoptosis and as a negative regulator of cell cycle progression. PKCd has been also implicated in cancer cell motility and invasiveness. Studies using animal models showed that PKCd can either act as a tumor suppressor or contribute to tumorigenesis depending on the context.
PKCe overexpressing breast cancer cells in mice enhances the incidence and number of spontaneous and experimental lung metastases. 95 Verma and coworkers 189, 190 generated skin transgenic mice expressing PKCe under the control of the human K14 promoter, which exhibit phenotypic abnormalities including inflammation, hyperkeratosis, hyperplasia, cellular hypertrophy and ulceration. Highly malignant and metastatic squamous cell carcinomas develop in the skin of PKCe transgenic mice. Additionally, PKCe overexpression has been shown to sensitize the mouse skin to UVR-induced carcinogenesis.
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A subsequent study demonstrated that skin transgenic PKCe mice develop a myeloproliferative-like disease. 192 Altogether, these observations establish that PKCe overexpression is linked to an aggressive phenotype and suggest that targeting PKCe could be an effective anticancer strategy. Whereas the development of PKCe inhibitors targeting the ATP-binding site may be challenging due to the high homology of this site among PKCs, agents directed against domains implicated in translocation may be valuable. In that regard, the PKCe translocation inhibitor eV1-2 has anti-tumorigenic activity in NSCLC cells 175 and a bifunctional peptide in which eV1-2 has been linked to the 12-mer cancer homing peptide HN1 impairs the growth of head and neck squamous cell carcinoma cells in xenografts. 193 Lastly, Ras-driven and epithelial-to-mesenchymal-dependent phenotypes in breast cancer cells could be reversed by PF-526355, an ATP mimetic inhibitor with selectivity for PKCe and PKCy. This inhibitor impairs the growth of MDA-MB-231 breast cancer xenografts in mice, thus representing a promising agent for cancer therapy. 194 ATYPICAL PKCS f AND i: OPPOSITE ROLES IN CANCER aPKC isozymes, which comprise PKCz and PKCi (PKCl), are structurally and functionally distinct from other PKCs in that they have a single DAG/phorbol ester unresponsive C1 domain and lack a C2 domain. 195, 196 Regardless of controversies in the literature largely due to the use of non-specific approaches such as inhibitory peptides and dominant-negative mutants, many studies point to a tumor suppressor function of PKCz, whereas PKCi essentially fulfills the criteria of an oncogenic kinase ( Figure 6 ).
Both up and downregulation of PKCz has been shown in human cancer. PKCz upregulation has been reported in prostate cancer, bladder cancer and lymphomas, [197] [198] [199] [200] [201] [202] whereas downregulated expression of PKCz has been shown in glioblastoma, lung cancer, kidney, renal clear cell carcinoma, melanoma and pancreatic cancer. [203] [204] [205] [206] [207] [208] [209] [210] [211] [212] A pro-apoptotic function for PKCz has been described in several cancer models. For example, PKCz inhibits growth and promotes differentiation and apoptosis in colon cancer cells. The inhibitory effect of PKCz on the transformed phenotype of these cells suggests that downregulation of PKCz may contribute to colon tumorigenesis. 213 PKCz also exhibits a pro-apoptotic function in ovarian cancer. 214 In murine TRAMP prostate cancer cells, expression of a constitutively activated PKCz mutant enhances proliferation, whereas PKCz inhibition leads to Akt activation and enhanced cell survival. 215 There are several reports, however, highlighting a pro-survival role for PKCz. [216] [217] [218] [219] [220] PKCz-deficient mice display increased Ras-induced lung carcinogenesis, arguing for a role for this aPKC as a tumor suppressor in vivo. It has been postulated that the tumor suppressor activity of PKCz occurs through its ability to downregulate Ras-induced interleukin-6 production. The enhanced secretion of interleukin-6 in PKCz-deficient Ras-transformed cells is essential for growth under conditions of limited nutrients and mitogens. 209 Genetic inactivation of PKCz in mice in a Pten-deficient background leads to invasive prostate carcinoma. A significant correlation between PKCz and Pten levels exists in human prostate tumors, and PKCz is significantly reduced in metastatic versus primary tumors with low Pten. Analysis of gene signatures in PKCz-deficient cells revealed a link with c-Myc. Indeed, c-Myc is a contributor to the more aggressive phenotype associated with PKCz loss. 221 Loss of PKCz also allows glucose-addicted human cancer cells to reprogram their metabolism in response to glucose deprivation by augmenting the utilization of glutamine through the serine biosynthetic pathway. 222 Accumulating evidence established that PKCi is an oncogenic kinase and that it contributes to the transformed phenotype. Overexpression of PKCi is observed in many human cancers, including colon, lung, pancreas, breast, prostate and ovarian cancer. The PKCi gene (PRKCI) is amplified in some human cancers, [223] [224] [225] although PKCi overexpression is not always associated with gene amplification. [226] [227] [228] This has been well summarized in a review by Murray et al. 229 PKCi expression is elevated in NSCLC tumors and cell lines, and is required for the transformed phenotype of NSCLC cells harboring oncogenic K-Ras mutation. [230] [231] [232] [233] NSCLC cell lines without Ras mutation also depend on PKCi for their malignant phenotype if they harbor PRKCI gene amplification. 233 PKCi mediates its effects through a Rac1-Pak-Mek-Erk-dependent mechanism. 88 By means of a proteomics approach, Justilien et al. 234 identified the Rho-GEF Ect2 as a component of the PKCiPar6 complex that is required for transformed growth. The Ect2 gene co-amplifies with PRKCI suggesting a coordinated mechanism for tumorigenesis. Disruption of the PKCi-Par6 interaction, as caused with the anti-rheumatic agent aurothiomalate, potently inhibits growth of PKCi-overexpressing cell lines. Anti-rheumatic agent aurothiomalate inhibits K-Rasmediated expansion of bronchoalveolar stem cells and lung tumor growth in vivo. 231, 235 On the other hand, aPKCs appear to be dispensable for mammalian hematopoietic stem cell function. 236 PKCi has been also implicated in colon and pancreatic cancer using cell lines and animal models. 227, 228 PKCi is required for hedgehog signaling in basal cell carcinomas. Indeed, PKCi functions downstream of smoothened (SMO) to phosphorylate and activate the GLI1 transcription factor. Moreover, PKCi is upregulated in tumors resistant to SMO inhibitors, and targeting PKCi suppresses the growth of resistant basal carcinoma cell lines. 237 Other interesting signaling connections have been established for PKCi, including mutually antagonistic regulation with RhoB in glioblastoma cell invasion, 238 links with the NF-kB pathway 239, 240 as well as association with cell cycle proteins cyclin E in ovarian cancer, 224 and S-phase kinase-associated protein 2 in esophageal cancer. 241 
FINAL REMARKS
Tangible progress has been made in the last 30 years in understanding the regulation and cellular functions of PKC isozymes in cancer. The picture that emerged, however, is less than clear. What we have learned over the last years is that the biology of PKC isozymes is exceptionally complex, and that many studies in cell lines do not necessarily apply to in vivo models. For the next wave of studies on PKC function, the generation of animal models recapitulating the scenarios observed in different cancer types should be a priority. However, it is still not known whether the activation status of different members of the PKC family is altered in cancer and whether activated PKCs functionally interact with oncogenes and tumor suppressors genes driving the tumorigenic and metastatic phenotype.
One would expect that PKC is a promising target for cancer therapy, but only for specific PKC isozymes that display oncogenic activity, such as PKCe and PKCi. The portfolio of available PKC inhibitors remains narrow, and unfortunately the majority of compounds lack specificity among members of the PKC family or even with other kinases unrelated to PKC. Hence, there is a great need to design selective small-molecule inhibitors for PKC isozymes that have sufficient potency to impair PKC function in vivo. There may be concrete opportunities to rationally design inhibitors against the ATP-binding site, but this is still challenging due to the high homology among PKCs in that region. Some examples of small molecules capable of disrupting proteinprotein interactions for PKC isozymes provided proof-of-principle for alternative approaches in the design of PKC modulators. 175, 235, 242 C1 domain ligands, such as the bryostatins, 243 ,244 did not show major beneficial effects in patients despite their anti-tumor effects in mice. 242 One may envision that PKC isozyme-specific inhibitors may possibly work in combined therapies with chemotherapeutic agents for discrete cancer types. Translating PKC modulators into a clinical setting remains a formidable challenge that we face for the next years.
